welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer jumps on 7-year-old data
Acer Therapeutics Inc. had a welcoming first week on the Nasdaq stock exchange, seeing shares sruge more 10% Monday after verifying positive clinical results published almost seven years ago from a study of celiprolol, the active ingredient in its lead drug candidate.
The study tested celiprolol against placebo in patients with vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening disorder that causes arteries and organs to easily rupture. After receiving treatment for about four years on average, 20% of the participants in the investigational arm experienced arterial events versus 50% of those in the control arm.
expertly curated content related to this topic
-
Ehlers-Danlos Syndrome – A Reference Guide (The Hill Resource and Reference Guide)The Hill Resource and Reference Guide se...
-
Ehlers-Danlos Syndrome in a DogEhlers-Danlos syndrome, also called cuta...
-
EDS: It Takes a Village – A Physical Therapist’s Role in an Integrative Approachhttps://www.youtube.com/watch?v=ml3R8Cpt...
-
My Disability | Ehlers Danlos Syndomehttps://www.youtube.com/watch?v=q7rRrV5y...
-
Sunshine and SpoonsI'm Hannah, a mom of four who loves Jesu...